Application of circPDK1

By using reagents to detect circPDK1 expression levels, a significant upregulation of circPDK1 in esophageal cancer was revealed. The encoded peptide PDK1-241aa promotes cancer cell growth, while knockdown of circPDK1 inhibits cancer cells. This provides a new method for esophageal cancer detection and prognostic evaluation, improving patient survival outcomes.

CN121320543AActive Publication Date: 2026-01-13KUNMING MEDICAL UNIVERSITY

Patent Information

Application Number
CN202511793884.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-02
Publication Date
2026-01-13
Estimated Expiration
2045-12-02

AI Technical Summary

Technical Problem

The lack of effective biomarkers and therapeutic targets for esophageal cancer in existing technologies leads to poor patient prognosis, and there is limited research on circRNA in esophageal cancer.

Method used

A reagent was developed to specifically detect the expression level of circPDK1 (hsa_circ_0057090) for the preparation of products for the detection of esophageal cancer and its prognostic evaluation. The expression level of circPDK1 is specifically upregulated in esophageal cancer patients. The encoded peptide PDK1-241aa can promote the proliferation and migration of esophageal cancer cells, and knockdown of circPDK1 can inhibit the growth of esophageal cancer cells.

Benefits of technology

circPDK1 and its encoded peptide PDK1-241aa are significantly upregulated in esophageal cancer, promoting cancer cell proliferation and migration. Knockdown of circPDK1 can inhibit the growth of esophageal cancer cells. Esophageal cancer patients with low expression have a longer average survival time than those with high expression, providing a new research direction for esophageal cancer detection and prognosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121320543A_ABST
    Figure CN121320543A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicines, discloses application of circPDK1 protection, and particularly relates to application of a reagent for specific detection of circPDK1 in preparation of products for detection of esophageal cancer or prognosis evaluation of esophageal cancer. According to the application of the protected circular RNA in preparation of the esophageal cancer detection product, the circular RNA is circPDK1, and the nucleotide sequence of the circular RNA is shown as SEQ ID NO: 1. Experiments prove that circPDK1 is highly expressed in esophageal cancer tissues, growth, proliferation and migration of esophageal cancer cells are promoted, occurrence of esophageal cancer is promoted, knock-down of the circular RNA can significantly inhibit growth, proliferation and migration of esophageal cancer tumors, and the average survival time of esophageal cancer patients with low circPDK1 expression is longer than that of esophageal cancer patients with high circPDK1 expression. And a new research direction is provided for esophageal cancer detection, treatment and prognosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, to the application of circPDK1 (hsa_circ_0057090), and particularly to the application of circPDK1 in the preparation of products for detecting esophageal cancer and evaluating its prognosis. Background Technology

[0002] Esophageal cancer is a common malignant tumor of the digestive tract, with 90% being squamous cell carcinoma. The 5-year survival rate for patients is less than 30%, and its incidence and mortality rates remain high globally. Early-stage esophageal cancer often presents with few or no clinical symptoms, and approximately 70% of cases are diagnosed at a locally advanced stage or with distant metastasis. Despite advancements in comprehensive treatment strategies such as radiotherapy, chemotherapy, and immunotherapy for esophageal cancer, the high metastasis rate, recurrence rate, and treatment resistance of esophageal squamous cell carcinoma (ESCC) result in poor prognoses for patients. Therefore, in-depth research into the molecular mechanisms of esophageal cancer development and progression, and the identification of effective drug targets, is of significant clinical importance for improving patient survival and quality of life.

[0003] circRNAs are a class of single-stranded, closed-loop, circular non-coding RNAs produced by backsplicing of pre-mRNA. Compared to linear RNAs, circRNAs lack a 5' cap and a 3' poly(A) tail, making them less susceptible to exonuclease effects and more stable in expression. circRNAs can participate in tumorigenesis and development by attaching to miRNAs, binding proteins, or encoding polypeptides. Due to their high stability and tissue-specific expression, circRNAs have become a new hot topic in tumor research, with the detection of circRNA-related biomarkers and the development of circRNA vaccines showing great promise. For example, patent CN117143999A discloses the application of a combination of circular RNAs as molecular markers for lung adenocarcinoma. This combination consists of circLZIC and circCEP350; by detecting their expression levels, it is possible to determine whether a subject has lung adenocarcinoma or is at risk of developing it. However, current research on the function of circRNAs and their encoded polypeptides in esophageal cancer remains limited. circRNAs exhibit significant differential expression in esophageal cancer tissues. For example, circ-ITCH was generally lowly expressed in 684 patients with esophageal squamous cell carcinoma (ESCC) and was positively correlated with ITCH gene expression, suggesting it could serve as a potential diagnostic biomarker. High-throughput gene chip analysis revealed differential expression of 267 circRNAs in ESCC tissues (92 upregulated and 175 downregulated). Among them, circTRPS1-2 significantly inhibited cancer cell proliferation and migration by suppressing ribosome production. circTRPS1-2 was significantly downregulated in ESCC tumors, potentially acting as a tumor suppressor against ESCC, and its low expression is indicative of poor prognosis.

[0004] circPDHK1 (also known as circPDK1, hsa_circ_0057090) is an exon circular RNA formed by backsplicing exons 2-8 of the pyruvate dehydrogenase kinase 1 (PDK1 or PDHK1) gene. Current research has found that circPDHK1, encoding PDHK1-241aa, promotes the growth and metastasis of clear cell renal cell carcinoma. A search revealed no studies on circPDK1 (hsa_circ_0057090) in esophageal cancer. Whether circPDK1 can serve as a biomarker for esophageal cancer has not yet been reported. Summary of the Invention

[0005] The purpose of this invention is to overcome the above-mentioned technical deficiencies and provide applications of circPDK1, particularly its application in the preparation of products for detecting esophageal cancer and evaluating its prognosis.

[0006] This invention protects the application of a reagent for specifically detecting the expression level of circPDK1 in the preparation of a reagent for detecting esophageal cancer. The circPDK1 is hsa_circ_0057090, and its nucleotide sequence is shown in SEQ ID NO: 1. The expression level of circPDK1 is specifically upregulated in the cancer tissue of esophageal cancer patients.

[0007] This invention protects the application of a reagent for specifically detecting circPDK1 expression levels in the preparation of products for prognostic evaluation of esophageal cancer patients. The circPDK1 is hsa_circ_0057090, and its nucleotide sequence is shown in SEQ ID NO: 1. Esophageal cancer patients with low circPDK1 expression have a longer average survival time than those with high expression.

[0008] Furthermore, the reagent for specifically detecting the expression level of circular RNA in esophageal cancer tissue contains primer sequences for detecting circPDK1 expression in esophageal cancer tissue, as shown in SEQ ID NO: 2 and SEQ ID NO: 3.

[0009] The present invention also protects the use of reagents for detecting the expression level of a polypeptide encoded by circPDK1 in the preparation of products for detecting esophageal cancer or for prognostic evaluation of esophageal cancer patients, wherein the polypeptide encoded by circPDK1 is PDK1-241aa, and its amino acid sequence is shown in SEQ ID NO: 4.

[0010] Compared with the prior art, the beneficial effects of the present invention are as follows: This invention reveals for the first time that circPDK1 (hsa_circ_0057090) is significantly upregulated in esophageal cancer tissues and has the ability to encode the peptide PDK1-241aa. circPDK1 and its encoded peptide PDK1-241aa can significantly promote the proliferation, migration, and invasion of esophageal cancer cells, indicating that they play a pro-cancer role in esophageal cancer. Furthermore, it demonstrates that knocking down this circular RNA can significantly inhibit the growth, proliferation, and migration of esophageal cancer cells. Moreover, esophageal cancer patients with low circPDK1 expression have a longer average survival time than those with high expression, providing a new research direction for esophageal cancer detection, treatment, and prognosis. Attached Figure Description

[0011] Figure 1 This is the screening of differentially expressed circRNAs with protein-coding capabilities in esophageal cancer in Example 1 of the present invention; Figure 1A shows the differential expression of circRNAs in adjacent and cancerous tissues of 10 pairs of esophageal cancer patients using a volcano plot. The orange blocks on the right represent circRNAs that are significantly upregulated in esophageal cancer tissues, and the green dots on the left represent circRNAs that are significantly downregulated in esophageal cancer tissues (|fold change|>1, P-value<0.05). The two gray dashed lines perpendicular to the horizontal axis in the volcano plot represent ±1, and the gray dashed line perpendicular to the vertical axis represents P=0.05. Figure 1 B involves taking the intersection of 190 significantly upregulated circRNAs with the Ribo-seq dataset (sequencing adjacent and cancerous tissues from 10 pairs of esophageal cancer patients), and combining the tumor-specific circRNA database and circPrimer 2.0 software to finally screen out 7 candidate circRNAs containing ORF and IRES elements and encoding proteins greater than 10 kDa. Figure 1 Figure C shows the RT-qPCR validation results of the seven candidate circRNAs in esophageal cancer cells. Figure 2 The images show the sequencing and amplification results of the circPDK1 gene. Figure 2 A shows a schematic diagram of the origin of the circPDK1 gene and the Sanger sequencing results of the circPDK1 specific sequence; Figure 2 B used cDNA and gDNA from esophageal cancer cells Eca109 and KYSE79 as templates, and amplified circPDK1 using divergent and convergent primers, with GAPDH as a negative control.

[0012] Figure 3 This is a comparative graph showing the effects of circPDK1 on the proliferation of esophageal cancer cells. Figure 3 Figure A shows the expression of circPDK1 in Eca109 esophageal cancer cells after constructing stably knocked-down circPDK1 cells and detecting it using RT-qPCR. Figure 3 Figure B shows the construction of circPDK1 overexpressing cells in KYSE450 and KYSE180 cells, and the detection of circPDK1 expression in KYSE450 and KYSE180 cells by RT-qPCR experiment. Figure 3 C represents the effect of circPDK1 knockdown on the cell viability of Eca109 cells in the CCK8 assay; Figure 3 D represents the effect of circPDK1 overexpression on cell viability of KYSE450 and KYSE180 cells in the CCK8 assay; Figure 3 E represents the effect of circPDK1 knockdown on the cell cloning ability of Eca109 cells in the plate cloning assay. Figure 3F represents the effect of circPDK1 overexpression on the cloning ability of KYSE450 and KYSE180 cells in plate cloning assays. The left side shows representative images, and the right side shows the quantitative statistical results. *P<0.05, **P<0.01, ***P<0.005. Statistical graphs show mean ± standard error (error bars), with n=3 for each data group. Figure 4 The effect of circPDK1 on the migration ability of esophageal cancer cells, among which Figure 4 A represents the effect of circPDK1 knockdown on the migration ability of esophageal cancer cells Eca109, as determined by a Transwell migration assay. Figure 4 B represents the effect of circPDK1 overexpression on the migration ability of esophageal cancer cells KYSE450 and KYSE180 as detected by the Transwell migration assay. Figure 5 The figure shows the analysis results of the circPDK1-encoded protein PDK1-241aa. Figure 5 A is a diagram of the RNA sequence analysis of circPDK1, where the blue area represents the ORF of circPDK1, the brown area represents the IRES structure, and the purple area represents the m6A site. Figure 5 B. Cytoplasmic and nuclear RNA was extracted from esophageal cancer cells Eca109 and KYSE70 using an RNA cytoplasmic and nuclear extraction kit, and the expression levels of circPDK1 and PDK1 in the cells were detected by RT-qPCR. Figure 5 C on the left shows the insertion of the full-length IRES sequence (IRES-WT) and two truncated sequences (IRES-Del-1 and IRES-Del-2) into the pGL3-Basic vector. Figure 5 C on the right shows the transfection of the corresponding plasmid in 293T, and the translation function of IRES was detected by dual-luciferase reporter gene assay; Figure 5 D on the left is a schematic diagram of the carrier of circPDK1-Flag; Figure 5 D shows the plasmid overexpressing circPDK1 (WT type) and the mutant plasmid lacking the start codon ATG (mut type) transfected in 293T cells. The expression of Flag was detected by Western blot experiment, and β-actin was used as an internal control. Figure 5 E represents the transfection of Vector, circPDK1-WT, and circPDK1-mut plasmids into KYSE450 cells, followed by immunoprecipitation assays to detect Flag expression. Figure 5 The F-sequence is the sequence recognized by the PDK1 antibody. Figure 5F represents the overexpression of circPDK1-WT and circPDK1-mut in esophageal cancer cells. The expression level of PDK1-241aa was detected by Western blot experiment, with β-actin as an internal reference. Figure 6 The image shows the results of circPDK1 promoting tumorigenesis in nude mice by encoding the protein PDK1-241aa. Figure 6 A and Figure 6 B shows a comparison of changes in tumor volume and tumor weight in KYSE450 esophageal cancer cells that were subcutaneously injected with stable overexpressions of circPDK1 and circPDK1-mut in nude mice. Figure 6 C and Figure 6 Figure D shows the comparison of tumor volume changes and tumor weight changes after subcutaneous injection of KYSE450 esophageal cancer cells stably overexpressing pCDH and PDK1-241aa into nude mice. Figure 7 This invention relates to Example 1, which describes the expression level of circPDK1 in clinical samples of esophageal cancer tumor tissue and the results of patient prognosis. Figure 7 A shows the immunohistochemical staining images of normal tissue and esophageal cancer tissue; Figure 7 B is a comparison chart of circPDK1 detection results in esophageal cancer clinical samples and adjacent clinical samples. Figure 7 Figure C shows a comparison of the effects of low and high circPDK1 expression on patient prognosis. Scale bar = 100 μm. p <0.05 or p <0.01 is considered statistically significant; Figure 8 This is a graph showing the expression levels of PDK1-241aa, the protein encoded by circPDK1, in esophageal cancer cells and clinical tissues. Figure 8 A shows the expression of PDK1-241aa in normal esophageal cells and esophageal cancer cells; Figure 8 B shows the expression of PDK1-241aa in 9 pairs of esophageal cancer adjacent and cancerous tissues. Detailed Implementation

[0013] The present invention will be further described below with reference to embodiments and accompanying drawings, but the present invention is not limited to the following embodiments. To make the objectives, technical solutions, and advantages of the present invention clearer, the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the present invention and are not intended to limit the present invention.

[0014] Materials and reagents Normal esophageal epithelial cells (HET-1A) and esophageal cancer cell lines Eca109, KYSE70, KYSE180, KYSE30, KYSE150, KYSE450, CAES17, TE-12, and TE-1) were provided by the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. RPMI 1640, DMEM, and 0.05% Trypsin were purchased from Gibco; fetal bovine serum was purchased from Royalcel; and CCK8 reagent was purchased from Meilunbio. Transwell double-layer plates were purchased from Corning, and crystal violet was purchased from Beyotime Biotechnology. Clinical samples from esophageal cancer patients were all obtained from the First Affiliated Hospital of Zhengzhou University.

[0015] Example 1: Screening of differentially expressed circRNAs with protein-coding capabilities in esophageal cancer We collected adjacent and cancerous tissues from 10 pairs of esophageal cancer patients, then collected RNA for circRNA-seq sequencing, and analyzed the transcriptome results. Figure 1 Results A showed that 190 circRNAs were significantly upregulated in esophageal cancer tissues. Figure 1 Results B showed that combining the results of 190 upregulated circRNAs with Ribo-seq sequencing (Ribo-seq sequencing of adjacent and cancerous tissues from 10 pairs of esophageal cancer patients), along with a tumor-specific circRNA database and circPrimer 2.0 software, and taking the intersection, ultimately identified 7 candidate circRNAs containing ORF and IRES elements and encoding proteins greater than 10 kDa: hsa_circ_0004495, hsa_circ_0057090, hsa_circ_0003683, hsa_circ_0057109, hsa_circ_0002343, hsa_circ_0051974, and hsa_circ_0072014. Primers for RT-qPCR were designed targeting the splicing sites of these circRNAs. Figure 1 As shown in C, circPDK1 (hsa_circ_0057090) was significantly upregulated in esophageal cancer cell lines compared to normal esophageal epithelial cells, and the upregulation consistency was better than other candidate circRNAs. Therefore, we will focus on circPDK1 for further research.

[0016] This invention provides a biomarker for esophageal cancer, wherein the biomarker is a circular RNA circPDK1; the nucleotide sequence of circPDK1 is shown in SEQ NO: 1. The nucleotide sequence of circPDK1 is:

[0017] This embodiment also provides a specific primer pair for amplifying circPDK1, as shown in SEQ ID NO: 2 and SEQ ID NO: 3. SEQ ID NO: 2 is ATGAGGATTTGACTGTGAAGGATCA, and SEQ ID NO: 3 is TCCTTAAAATCAAGAAGCTCCTGAA.

[0018] Figure 2 A showed that circPDK1 originates from the PDK1 gene located in subband 1 of region 3 of chromosome 2, formed by reverse splicing and circularization of exons 2-8 of the PDK1 gene. Sanger sequencing results identified a specific adapter sequence for circPDK1 in esophageal cancer cells. To further validate circPDK1, genomic DNA (gDNA) from Eca109 and KYSE70 and complementary DNA (cDNA) obtained from reverse transcription of RNA were used as templates. Amplification was performed using divergent primers (SEQ ID NO: 2 and SEQ ID NO: 3) and convergent primers (circ_PDK1_Cov-F: CTTTACAGATACTGTGATACGGATC (SEQ ID NO: 20) and circ_PDK1_Cov-R: AGTGCTGATTGAGTAACATTCTAAT (SEQ ID NO: 21) for circPDK1. The results are as follows: Figure 2 As shown in B, the divergent primers of circPDK1 amplified bands in cDNA but not in gDNA, while the converging primers of circPDK1 amplified bands in both cDNA and gDNA.

[0019] Example 2: Effects of circPDK1 on the growth, proliferation, and migration of esophageal cancer cells A circPDK1 knockdown cell line was constructed using the shRNA method to knock down the expression level of the target RNA. For circPDK1, the knockdown target sequence across the circRNA splice site was analyzed using circinteractome (https: / / circinteractome.nia.nih.gov / ), and the designed shRNA sequence and oligonucleotide sequences used to construct the shRNA plasmid were synthesized by Beijing Qingke Biotechnology Co., Ltd. The nucleotide sequence of the shRNA sh-circPDK1#1 is shown in SEQ ID NO: 5, and the nucleotide sequence of sh-circPDK1#2 is shown in SEQ ID NO: 6. The nucleotide sequence of the control shRNA sh-Ctrl is SEQ ID NO: 4. The shRNA sh-circPDK1#1 plasmid that inhibits circPDK1 expression was constructed from oligonucleotide sequences SEQ ID NO: 9 and SEQ ID NO: 10; or from oligonucleotide sequences SEQ ID NO: 11 and SEQ ID NO: 12; the control shRNA sh-circPDK1#2 plasmid was constructed from oligonucleotide sequences SEQ ID NO: 7 and SEQ ID NO: 8. A lentiviral plasmid overexpressing circPDK1 was constructed using the lentiviral expression vector pLC5-ciR. The lentiviral overexpression plasmid was synthesized by Shanghai Jereh Biotechnology Co., Ltd. Complementary single-stranded oligonucleotides were annealed and renatured to form a double-stranded DNA with sticky ends, which was then ligated into the pLKO.1 vector using T4 DNA ligase (the pLKO.1 vector was digested and recovered using AgeI and EcoRI enzymes). The ligation product was transformed into DH5α competent cells, positive clones were screened, and the cells were expanded to single gram culture for plasmid extraction.

[0020]

[0021] After successful construction of the sh-circPDK1#1 plasmid, the sequencing sequence is shown in SEQ ID NO: 13; after successful construction of the sh-circPDK1#2 plasmid, the sequencing sequence is shown in SEQ ID NO: 14; and the circPDK1 overexpression plasmid sequence is shown in SEQ ID NO: 15.

[0022] Lentiviral circPDK1 knockdown and overexpression plasmids and lentiviral packaging plasmids were transfected into 293T cells to prepare viral fluid. Esophageal cancer cells Eca109, KYSE450, and KYSE180 were infected with the viral fluid and screened with puromycin. Cells were then collected, total RNA was extracted, and circPDK1 expression levels were detected by RT-qPCR to verify the successful construction of knockdown and overexpression cell lines. The stable transfected cell lines were then subjected to CCK8 assays and plate colony assays to detect tumor cell proliferation. The results are as follows: Figure 3 As shown.

[0023] like Figure 3 As shown, the results indicated that knockdown of cricPDK1 inhibited cell proliferation and plate colony formation, while overexpression of cricPDK1 promoted cell proliferation and plate colony formation. Figure 3 As shown in Figure A: Stable knockdown cells of circPDK1 were constructed in esophageal cancer cells Eca109. The expression of circPDK1 in Eca109 cells was detected by RT-qPCR. The results showed that circPDK1 was significantly reduced in Eca109 cells. Figure 3 As shown in Figure B, circPDK1 overexpressing cells were constructed in KYSE450 and KYSE180 cells. The expression of circPDK1 in KYSE450 and KYSE180 cells was detected by RT-qPCR. The results showed that circPDK1 expression was significantly increased in both KYSE450 and KYSE180 cells. Figure 3 As shown in C: Knockdown of circPDK1 inhibited cell viability in Eca109 cells in the CCK8 assay; Figure 3 D represents the effect of overexpression of circPDK1 on enhancing cell viability in KYSE450 and KYSE180 cells in the CCK8 assay. Figure 3 E shows that knockdown of circPDK1 inhibits cell cloning in Eca109 cells in a plate cloning assay; Figure 3 F showed that overexpression of circPDK1 enhanced the cell cloning ability of KYSE450 and KYSE180 cells in plate colony formation assays. These experimental results indicate that knockdown of circPDK1 inhibits cell proliferation and plate colony formation, while overexpression of circPDK1 significantly promotes cell proliferation and plate colony formation, suggesting that circPDK1 plays an important role in promoting cell proliferation and colony formation in esophageal cancer cells, and is crucial in the development and progression of esophageal cancer. Knockdown of circPDK1 inhibits cell migration, while overexpression of circPDK1 significantly enhances cell migration. Figure 4 ).

[0024] Example 3: circPDK1 encodes protein PDK1-241aa First, the RNA sequence of circPDK1 was analyzed. Figure 5 Results A showed that the cricPDK1 sequence contains an ORF (blue region) of 726 nt in length, which can serve as a template for translating a protein PDK1-241aa with 241 amino acids. The amino acid sequence of the protein PDK1-241aa is shown in SEQ ID NO: 16.

[0025] circPDK1 contains IRES structures (brown region) and m6A sites (purple region). Next, the localization of circPDK1 in the cytoplasm and nucleus was examined. Figure 5 Results B showed that circPDK1 is mainly located in the cytoplasm. The IRES element is one of the most important structures for circRNA to initiate its protein translation function, thus this study investigated whether the IRES element of circPDK1 possesses the function of initiating protein translation. A full-length IRES sequence (IRES-WT) and two truncated sequences (IRES-Del-1 and IRES-Del-2) were inserted into the pGL3-Basic vector, and the translation-initiating function of IRES was verified using a dual-luciferase reporter gene assay. The nucleotide sequence of the full-length IRES sequence (IRES-WT) is shown in SEQ ID NO: 17. The nucleotide sequences of the two truncated IRES sequences (IRES-Del-1 and IRES-Del-2) are as follows: IRES-Del-1 is shown in SEQ ID NO: 18; IRES-Del-2 is shown in SEQ ID NO: 19.

[0026] The results are as follows Figure 5 As shown, Figure 5 The results showed that, compared with the empty vector, IRES-WT effectively promoted protein expression, while the truncated IRES significantly inhibited its translation function, indicating that the IRES element of circPDK1 has the function of initiating protein translation. Furthermore, the circPDK1 sequence was ligated into the pLO5-ciR vector, and a Flag tag was inserted to construct a circPDK1 overexpression plasmid (WT type). Simultaneously, a plasmid with an ATG mutation in the start codon (mut type) was constructed, preventing it from encoding the protein. Figure 5 Results showed that a Flag band was detected after transfection with the WT plasmid, but no corresponding band was detected after transfection with the mut plasmid. Furthermore, IP experiments further demonstrated that circPDK1 has the potential to translate proteins. Figure 5The E results showed that a Flag band was detected after overexpression of circPDK1, while no Flag band was detected after expression of the mutated plasmid, indicating that circPDK1 can translate the protein. Further analysis of the expression of its encoded protein, PDK1-241aa, was conducted. Figure 5 The results showed that overexpression of circPDK1 increased PDK1-241aa protein expression, while the expression of PDK1-241aa protein was not significant after the start codon ATG mutation. These results indicate that circPDK1 can translate the protein PDK1-241aa.

[0027] Example 4: circPDK1 promotes tumor formation in nude mice by encoding the protein PDK1-241aa. To investigate how circPDK1 promotes tumorigenesis in nude mice by encoding PDK1-241aa, a subcutaneous xenograft model was constructed. Vector cells, KYSE450 cells stably overexpressing circPDK1, circPDK1-mut, and PDK1-241aa were seeded into the subcutaneous tissue of the backs of nude mice to establish a subcutaneous xenograft model. After tumor formation, tumor size was measured every 3 days. The nude mice were sacrificed after 30-40 days, and the subcutaneous tumor tissue was isolated and weighed.

[0028] The results are as follows Figure 6 As shown, Figure 6 Results A and 6B showed that, compared to the control group, overexpression of circPDK1 resulted in increased tumor volume and weight, while ATG mutation in circPDK1 did not promote tumor growth. Furthermore, Figure 6 Results from C and 6D studies showed that overexpression of PDK1-241aa led to increased tumor volume and weight. These results indicate that circPDK1 promotes tumorigenesis in nude mice by encoding the protein PDK1-241aa.

[0029] Example 5: Application of circular RNA circPDK1 in the detection of esophageal cancer Clinical application: In situ hybridization was used to detect circPDK1 expression in esophageal cancer clinical samples from 114 patients with squamous cell carcinoma of the esophagus and 66 esophageal mucosal samples (sample and patient prognostic information were obtained from Shanghai Xinchao Biotechnology Co., Ltd.).

[0030] The results are as follows Figure 7 As shown, Figure 7Image A shows immunohistochemical staining of normal tissue and esophageal cancer tissue, indicating that circPDK1 is highly expressed in esophageal cancer tissue compared to adjacent normal tissue. Samples were scored, with staining intensity categorized as 0 (negative), 1 (weak), 2 (moderate), and 3 (strong); the percentage of positive cells was categorized as 0 (negative), 1 (1-25%), 2 (26-50%), 3 (51-75%), and 4 (76-100%). A staining score <8 indicates low expression, and >8 indicates high expression. Figure 7 B shows the detection results of circPDK1 in esophageal cancer clinical samples from 114 esophageal cancer patients and 66 adjacent clinical samples, indicating that circPDK1 is highly expressed in esophageal cancer tissues. Figure 7 The results showed that patients with high circPDK1 expression had shorter survival and worse prognosis than those with low circPDK1 expression, indicating that circPDK1 has the function of detecting esophageal cancer or evaluating the prognosis of esophageal cancer patients.

[0031] Example 6: Application of the polypeptide PDK1-241aa encoded by circular RNA circPDK1 in the detection of esophageal cancer. Normal human esophageal cells (HET-1A) and esophageal cancer cells (Eca109, KYSE70, KYSE180, KYSE430, KYSE150, KYSE450, CAES17, TE-12, TE-1) were collected, and the expression of PDK1-241aa protein was detected by Western bot assay.

[0032] The results are as follows Figure 8 As shown, Figure 8 A indicates that PDK1-241aa is expressed at increased levels in esophageal cancer cells compared to normal esophageal cells; Figure 8 B shows the expression of PDK1-241aa in nine pairs of esophageal cancer adjacent and cancerous tissues, indicating that PDK1-241aa is highly expressed in esophageal cancer tissues. This demonstrates that detecting the expression level of the polypeptide PDK1-241aa encoded by the circular RNA circPDK1 can be used to detect esophageal cancer.

Claims

1. The application of a reagent for specifically detecting circPDK1 expression levels in the preparation of reagents for detecting esophageal cancer, characterized in that: The circPDK1 is hsa_circ_0057090, and its nucleotide sequence is shown in SEQ ID NO:

1. The expression level of circPDK1 is specifically upregulated in the cancer tissue of esophageal cancer patients.

2. The application of a reagent specifically for detecting circPDK1 expression levels in the preparation of products for prognostic evaluation of esophageal cancer patients, characterized by: The circPDK1 is hsa_circ_0057090, and its nucleotide sequence is shown in SEQ ID NO:

1. Esophageal cancer patients with low expression of circPDK1 have a longer average survival time than patients with high expression.

3. The application as described in claim 1 or 2, characterized in that: The reagent for specifically detecting circPDK1 expression levels contains primer sequences for detecting circPDK1 expression in esophageal cancer tissues, as shown in SEQ ID NO: 2 and SEQ ID NO:

3.

4. The application of a reagent for detecting the expression level of the circPDK1-encoded peptide in the preparation of products for detecting esophageal cancer or for prognostic evaluation of esophageal cancer patients, characterized in that... The polypeptide encoded by circPDK1 is PDK1-241aa, and its amino acid sequence is shown in SEQ ID NO: 4.

Citation Information

Patent Citations

  • Application of circular RNA combination as lung adenocarcinoma molecular marker

    CN117143999A

  • Application of targeting miR-493 / HIF-1alpha / PDK1 in preparation of drug-resistant drugs

    CN114177293A

  • Application of PDK1 protein or coding gene thereof as target spot in preparation of medicine for treating systemic lupus erythematosus

    CN118356493A

  • Application of hsacirc0008581 as biomarker for esophageal cancer auxiliary diagnosis and / or esophageal cancer patient prognosis prediction

    CN119082302A

  • Application of reagent for targeted inhibition of circPDK1 in preparation of anti-esophageal cancer drugs

    CN121221631A

Cited By

  • Application of reagent for targeted inhibition of circPDK1 in preparation of anti-esophageal cancer drugs

    CN121221631A

  • Use of an agent targeting and inhibiting circPDK1 in the preparation of an anti-esophageal cancer drug

    CN121221631B

  • Application of reagent for targeted delivery of circAMY2B in preparation of anti-esophageal cancer drugs

    CN122208553A